Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
An open clinical trial of a 23-valent pneumococcal polysaccharide vaccine (PPV23) developed by Sinovac Life Science Co., Ltd was conducted to evaluate the safety of Sinovac PPV23 in target population of individuals aged 2 years and above. All participants received 1 dose of PPV23 and self-selected whether to receive 1 dose of influenza vaccine at the same time.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Acitive safety surveillance group |
| ||
| Passive safety surveillance group |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 23-valent pneumococcal polysaccharide vaccine | Biological | 23-valent pneumococcal polysaccharide vaccine |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of adverse reactions to 23-valent pneumonia vaccine within 0-28 days after single and combined vaccination. | 28 days after the vaccination |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of adverse events to 23-valent pneumonia vaccine within 0-28 days after single and combined vaccination. | 28 days after the vaccination | |
| Incidence of adverse events to 23-valent pneumonia vaccine within 0-7 days after single and combined vaccination. |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Participants aged 2 years old and above.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Jiangsu Provincial Center for Disease Prevention and Control | Nanjing | Jiangsu | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41729368 | Derived | Shi YF, Ju LH, Wang KN, Pan Y, Zou YY, Lu X, Tuo L, Zou WT, Wei MW, Zhao YW, Pan HX. Post-marketing Safety Surveillance of 23-Valent Pneumococcal Polysaccharide Vaccine Administered Alone and Concomitantly with Influenza Vaccine in Individuals Aged 2 Years and Older in China. Infect Dis Ther. 2026 Apr;15(4):1035-1046. doi: 10.1007/s40121-026-01309-4. Epub 2026 Feb 23. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011008 | Pneumococcal Infections |
| ID | Term |
|---|---|
| D013290 | Streptococcal Infections |
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
Not provided
Not provided
| ID | Term |
|---|---|
| C414006 | 23-valent pneumococcal capsular polysaccharide vaccine |
| D007252 | Influenza Vaccines |
| ID | Term |
|---|---|
| D014765 | Viral Vaccines |
| D014612 | Vaccines |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
Not provided
Not provided
Not provided
Not provided
Not provided
| Influenza vaccine | Biological | Influenza vaccine |
|
| 7 days after the vaccination |
| D007239 | Infections |